降糖药物对2型糖尿病患者β细胞应答与胰岛素敏感性的纵向影响:GRADE随机临床试验
在GRADE研究2型糖尿病队列(n=4801)中,比较二甲双胍基础上加用甘精胰岛素U-100、格列美脲、利拉鲁肽或西格列汀对胰岛素敏感性和β细胞功能的长期影响。结果显示各药对胰岛素敏感性和β细胞功能的影响存在差异,突显β细胞功能丧失在2型糖尿病进展中的重要性。
要点
- 甘精胰岛素组HOMA2-%S从基线至第1年升高,此后保持稳定;其他组HOMA2-%S较基线无变化。
- 所有组HOMA2-%B和C肽应答在第1年有不同程度升高,随后随时间逐渐下降。
- 第5年CPI利拉鲁肽与西格列汀相似且均高于甘精胰岛素和格列美脲,总C肽应答利拉鲁肽最高、格列美脲最低。
核心结论
- 二甲双胍基础上加用四种不同降糖药物对胰岛素敏感性和β细胞功能的长期影响存在差异,突显β细胞功能丧失在2型糖尿病进展中的重要性。
研究设计与样本
- GRADE(血糖降低方法比较有效性研究)队列,纳入2型糖尿病患者n=4801,在基线及治疗第1、3、5年评估HOMA2胰岛素敏感性(HOMA2-%S)和空腹β细胞功能(HOMA2-%B)。
- 在同一时间点评估口服葡萄糖耐量试验β细胞应答(C肽指数[CPI]和总C肽应答[120分钟内增量C肽/增量葡萄糖])。
- 在回归分析中校正HOMA2-%S后的应答提供β细胞功能的估计。
主要发现
- HOMA2-%S从基线至第1年在甘精胰岛素组升高,此后保持稳定;其他治疗组HOMA2-%S较基线无变化。
- 所有组HOMA2-%B和C肽应答在第1年有不同程度升高,但随后随时间逐渐下降。
- 第5年CPI利拉鲁肽与西格列汀相似,且两者均高于甘精胰岛素和格列美脲[分别为0.80、0.87、0.74和0.64 (nmol/L)/(mg/dL) * 100,P < 0.001]。
- 第5年总C肽应答以利拉鲁肽最高,依次下降为西格列汀、甘精胰岛素和格列美脲[分别为1.54、1.25、1.02和0.87 (nmol/L)/(mg/dL) * 100,P < 0.001]。
- 校正HOMA2-%S以获得β细胞功能估计后,β细胞应答的变化性质反映了β细胞功能的变化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the long-term effects of glucose-lowering medications (insulin glargine U-100, glimepiride, liraglutide, and sitagliptin) when added to metformin on insulin sensitivity and β-cell function. RESEARCH DESIGN AND METHODS: In the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) cohort with type 2 diabetes (n = 4,801), HOMA2 was used to estimate insulin sensitivity (HOMA2-%S) and fasting β-cell function (HOMA2-%B) at baseline and 1, 3, and 5 years on treatment. Oral glucose tolerance test β-cell responses (C-peptide index [CPI] and total C-peptide response [incremental C-peptide/incremental glucose over 120 min]) were evaluated at the same time points. These responses adjusted for HOMA2-%S in regression analysis provided estimates of β-cell function. RESULTS: HOMA2-%S increased from baseline to year 1 with glargine and remained stable thereafter, while it did not change from baseline in the other treatment groups. HOMA2-%B and C-peptide responses were increased to variable degrees at year 1 in all groups but then declined progressively over time. At year 5, CPI was similar between liraglutide and sitagliptin, and higher for both than for glargine and glimepiride [0.80, 0.87, 0.74, and 0.64 (nmol/L)/(mg/dL) * 100, respectively; P < 0.001], while the total C-peptide response was greatest with liraglutide, followed in descending order by sitagliptin, glargine, and glimepiride [1.54, 1.25, 1.02, and 0.87 (nmol/L)/(mg/dL) * 100, respectively, P < 0.001]. After adjustment for HOMA2-%S to obtain an estimate of β-cell function, the nature of the change in β-cell responses reflected those in β-cell function. CONCLUSIONS: The differential long-term effects on insulin sensitivity and β-cell function of four different glucose-lowering medications when added to metformin highlight the importance of the loss of β-cell function in the progression of type 2 diabetes.
引用
- Rasouli N, Younes N, Ghosh A, et al. Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial. Diabetes Care. 2024. PMID: 38211595. doi:10.2337/dc23-1070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。